- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
30matching registry records
Matching recruiting site observations19
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 3 matching recruitingBowie, Maryland, 20715, United States / Ft. Washington, Maryland, 20744, United States / Rockville, Maryland, 20850, United States | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 1 matching recruitingColumbia, Maryland, 21045, United States | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 2 matching recruitingBaltimore, Maryland, 21239, United States / Hyattsville, Maryland, 20782, United States | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 / ENLIGHTEN-3 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3800 estimated | 1 matching recruitingBowie, Maryland, 20715, United States | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07369011 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 1 matching recruitingColumbia, Maryland, 21045, United States | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 / Enith2 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 31,600 estimated | 1 matching recruitingColumbia, Maryland, 21045-5840, United States | Aug 7, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351058 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 3 matching recruitingBaltimore, Maryland, 21229, United States / Oxon Hill, Maryland, 20745, United States / Rockville, Maryland, 20854, United States | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 4 matching recruitingBaltimore, Maryland, 21229, United States / Baltimore, Maryland, 21287, United States / Beltsville, Maryland, 20705, United States / 1 more area | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 / Amgen | RecruitingVerified 2026-06 | Phase 2180 estimated | 1 matching recruitingGlen Burnie, Maryland, 21061, United States | Sep 29, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07441252 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 2 matching recruitingBaltimore, Maryland, 21202, United States / Chevy Chase, Maryland, 20815, United States | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 / AMAZE 8 / Novo Nordisk A/S | Not yet recruitingVerified 2026-03 | Phase 31,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 12, 2028estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07400107 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 / Novo Nordisk A/S | Active, not recruitingVerified 2025-12 | Phase 2142 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 21, 2026estimated | Dec 5, 2025ClinicalTrials.gov | Open NCT06797869 ↗ |
| A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 / Carmot Therapeutics, Inc. | Active, not recruitingVerified 2026-06 | Phase 2447 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 29, 2026actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06628362 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 / MARITIME-2 / Amgen | Active, not recruitingVerified 2025-12 | Phase 31,105 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 21, 2027estimated | Dec 31, 2025ClinicalTrials.gov | Open NCT06858878 ↗ |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,250 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT06260722 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 / TRIUMPH-8 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 3250 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 2027estimated | Apr 17, 2026ClinicalTrials.gov | Open NCT07232719 ↗ |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2026-04 | Phase 31,100 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2027estimated | Apr 7, 2026ClinicalTrials.gov | Open NCT07104383 ↗ |
| VK2735 for Weight Management Phase 3NCT07104500 / VANQUISH 1 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2025-11 | Phase 34,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2027estimated | Nov 24, 2025ClinicalTrials.gov | Open NCT07104500 ↗ |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 2448 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 1, 2025actual | Dec 29, 2025ClinicalTrials.gov | Open NCT06542874 ↗ |
| Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047 / Novo Nordisk A/S | CompletedVerified 2024-07Registry results posted | Phase 2706 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2, 2020actual | Jul 5, 2024ClinicalTrials.gov | Open NCT03856047 ↗ |
| Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 / Novo Nordisk A/S | CompletedVerified 2025-12Registry results posted | Phase 292 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 7, 2022actual | Dec 23, 2025ClinicalTrials.gov | Open NCT04982575 ↗ |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2698 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 17, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT05016882 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/S | CompletedVerified 2026-04 | Phase 31,024 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 4, 2026actual | Apr 22, 2026ClinicalTrials.gov | Open NCT06221969 ↗ |
| A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 / Eli Lilly and Company | CompletedVerified 2023-06Registry results posted | Phase 2281 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 8, 2022actual | Jul 3, 2023ClinicalTrials.gov | Open NCT04867785 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →